Evidence map›Paper›PMID 34919585›Full record

ArticlePloS one2021

Characteristics of opioid prescribing to outpatients with chronic liver diseases: A call for action.

Olufunso M Agbalajobi, Theresa Gmelin, Andrew M Moon, Wheytnie Alexandre, Grace Zhang, Walid F Gellad, Naudia Jonassaint, Shari S Rogal

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Hepatic Encephalopathy: Current Thoughts on Pathophysiology and Management.Current neurology and neuroscience reports · 2025
    Review
  3. Article
  4. Changing Epidemiology of Cirrhosis and Hepatic Encephalopathy.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Olufunso M AgbalajobiDepartment of General Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, United States of America.
Theresa GmelinDepartment of Biostatistics, University of Pittsburgh, Pittsburgh, PA, United States of America.
Andrew M MoonDivision of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.ORCID 0000-0001-7163-2062
Wheytnie AlexandreUniversity of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America.
Grace ZhangUniversity of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America.
Walid F GelladDivision of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, United States of America.
Naudia JonassaintDivision of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh, Pittsburgh, PA, United States of America.ORCID 0000-0002-6859-2909
Shari S RogalCenter for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, University Drive, Pittsburgh, PA, United States of America.ORCID 0000-0001-8184-1546
University of Pittsburgh · USUniversity of North Carolina at Chapel Hill · USUniversity of Pittsburgh Medical Center · US

Funding

The University of Pittsburgh's Comparative Effectiveness Research Scholars PrograK12HS019461 · AHRQ · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAPOOR, WISHWA N · 2010 to 2010
$1.9M
Improving Pain Management and Opioid Safety for Patients with CirrhosisK23DA048182 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ROGAL, SHARI S · 2020 to 2023
$755k
AHRQ HHS K12 HS019461NIDA NIH HHS K23 DA048182
6 · The paper itself

Abstract

backgroundChronic liver disease (CLD) is among the strongest risk factors for adverse prescription opioid-related events. Yet, the current prevalence and factors associated with high-risk opioid prescribing in patients with chronic liver disease (CLD) remain unclear, making it challenging to address opioid safety in this population. Therefore, we aimed to characterize opioid prescribing patterns among patients with CLD.

methodsThis retrospective cohort study included patients with CLD identified at a single medical center and followed for one year from 10/1/2015-9/30/2016. Multivariable, multinomial regression was used identify the patient characteristics, including demographics, medical conditions, and liver-related factors, that were associated with opioid prescriptions and high-risk prescriptions (≥90mg morphine equivalents per day [MME/day] or co-prescribed with benzodiazepines).

resultsNearly half (47%) of 12,425 patients with CLD were prescribed opioids over a one-year period, with 17% of these receiving high-risk prescriptions. The baseline factors significantly associated with high-risk opioid prescriptions included female gender (adjusted incident rate ratio, AIRR = 1.32, 95% CI = 1.14-1.53), Medicaid insurance (AIRR = 1.68, 95% CI = 1.36-2.06), cirrhosis (AIRR = 1.22, 95% CI = 1.04-1.43) and baseline chronic pain (AIRR = 3.40, 95% CI = 2.94-4.01), depression (AIRR = 1.93, 95% CI = 1.60-2.32), anxiety (AIRR = 1.84, 95% CI = 1.53-2.22), substance use disorder (AIRR = 2.16, 95% CI = 1.67-2.79), and Charlson comorbidity score (AIRR = 1.27, 95% CI = 1.22-1.32). Non-alcoholic fatty liver disease was associated with decreased high-risk opioid prescriptions (AIRR = 0.56, 95% CI = 0.47-0.66).

conclusionOpioid medications continue to be prescribed to nearly half of patients with CLD, despite efforts to curtail opioid prescribing due to known adverse events in this population.

Indexed as

Analgesics, OpioidChronic PainDrug PrescriptionsFemaleHumansLiver DiseasesMaleMiddle AgedOpioid-Related DisordersOutpatientsPractice Patterns, Physicians'Retrospective StudiesUnited StatesAnalgesics, Opioid

Identifiers

PMID34919585
PMCPMC8682904
OpenAlexW4200178213

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.